May 8, 2020
May 7, 2020
May 7, 2020 –
The U.S. FDA has approved TabrectaTM (capmatinib), manufactured by Novartis, to treat
adult patients who have metastatic non-small cell lung cancer (NSCLC) and
May 6, 2020
May 6, 2020 –
The U.S. FDA has approved a new indication for Farxiga® (dapagliflozin) oral tablets,
manufactured by AstraZeneca. The drug is now indicated to reduce the risk of
May 4, 2020
May 4, 2020 –
The U.S. FDA has approved Fensolvi® (leuprolide acetate), manufactured by Tolmar
Pharmaceuticals, to treat pediatric patients two years of age and older who
March 18, 2020
May 18, 2020 –
The U.S FDA has approved a new indication for Tecentriq® (atezolizumab), manufactured
by Genentech, to provide initial
March 15, 2020
May 15, 2020 –
The U.S. FDA has approved a new indication for Opdivo® (nivolumab – Bristol Myers Squibb), used in combination with Yervoy® (ipilimumab – Bristol Myers Squibb)
January 23, 2020
January 23, 2020 – The U.S. FDA has granted accelerated approval to TazverikTM (tazemetostat),
manufactured by Epizyme, to treat patients who are at least 16 years old and have metastatic or locally
January 21, 2020
January 21, 2020 – The U.S. FDA has approved TepezzaTM (teprotumumab-trbw), manufactured by Horizon
Therapeutics, to treat thyroid eye disease (TED). It is the first and only FDA-approved therapy for this
indication.